The six-month patient crossover occurred when patients enrolled in the study switched from using a placebo to RPI-78M and those patients currently taking RPI-78M began using a placebo. RPI-78M is ReceptoPharm’s lead drug candidate for the treatment of neurological and autoimmune disorders.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy).
Paul Reid, CEO of ReceptoPharm, said: “This is an important milestone in our clinical development process, as successful completion of this crossover acts as an early indication that our trial is running smoothly.”